India Cements Ltd
INDIACEMIndia Cements Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the P/E sits at the 83rd percentile of its own range — the multiple has already done part of the work.
The price is in a downtrend (1 weeks in) while the P/E sits at the 83rd percentile of its own 10-year range. Underneath, the last four quarters read mixed, and 539% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
India Cements Ltd trades at ₹375, in a downtrend and 1 weeks into that stage. That is −4.1% against its own 200-day average. It sits at 17% of a 52-week range of ₹354 to ₹479. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (2 weeks and counting).
Today the stock is in a downtrend — week 1 of stage 4, confirmed. At ₹375 it trades −4.1% versus its 200-day average and sits at 17% of its 52-week range (₹354–₹479).
Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +456% while the NIFTY 500 moved +284% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-07-31) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
India Cements Ltd trades at 86.2× P/E, at the pricey end of its own range (83rd percentile). Its long-run median P/E is 41.9×, measured across 10.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 86.2× is at the pricey end of its own range (83rd percentile), against a long-run median of 41.9× measured over 10.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
The price move, decomposed: over 5y, of the +16.2%/yr price move, ~−10.1%/yr came from earnings growth and ~+26.3 pp from the multiple (expanding); over 10y, of the +11.9%/yr price move, ~+1.2%/yr came from earnings growth and ~+10.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
India Cements Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 12 quarters across 2 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +8.3% | −7.2% | −0.1% | −0.8% |
| Share price | +1.7% | +14.1% | +16.2% | +11.9% |
4-Factor Sector Score
44.8/100 — rank 15 of 26 in Cement · 75% evidence confidence
India Cements Ltd scores 44.8 out of 100 against the 26 companies it is compared with in Cement, ranking 15. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 21 + 3.7 + 5.9 + 14.2 = 44.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
India Cements Ltd reported ₹1,019 Cr of revenue in the Jun 26 quarter, −0.6% year on year. Over 10 years it has compounded at −0.8% a year. The last full year, FY26, came in at ₹4,485 Cr. The last four reported quarters add to ₹4,479 Cr.
FY26 revenue came in at ₹4,485 Cr (+8.3% on the year), capping 10 years at −0.8% compound. The latest quarter (Jun 26) printed ₹1,019 Cr, −0.6% year on year.
Pace check: the last four quarters averaged +7.5% growth against the decade's −0.8% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +7.0% over the last 4 quarters against −1.8%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
India Cements Ltd's operating margin is 15.0% in the Jun 26 quarter, +7.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −8.0% to 18.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 15.0%, +7.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged −8.0%–18.0%.
Why the margin moved: operating margin went +7.2 pp year on year while gross margin went −12.0 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
India Cements Ltd earned ₹27.0 Cr of net profit in the Jun 26 quarter. The full FY26 year was a loss of ₹67.0 Cr. That is 2.6% of the quarter's revenue. The same quarter a year earlier lost ₹133 Cr. 5 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹27.0 Cr, null year on year. On the full year, FY26 printed ₹−67.0 Cr (null).
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 539% of India Cements Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹−27.0 Cr of operating cash against ₹−67.0 Cr of profit. After ₹15.0 Cr of capital spending, ₹−42.0 Cr was left as free cash.
FY26: operating cash of ₹−27.0 Cr against reported profit of ₹−67.0 Cr, leaving free cash of ₹−42.0 Cr after ₹15.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 539% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 539%: the cash cycle stretched 145 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 6.8× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
India Cements Ltd's cash conversion cycle runs −28 days in FY26, up from −173 days in FY21. Capital spending ran ₹5,173 Cr over the last 3 years. At FY26 sales of ₹4,485 Cr each day of that cycle holds about ₹12.3 Cr, so roughly ₹−344 Cr sits inside the business at any moment.
FY26: debtors at 20 days, inventory at 269 days — roughly 8.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −28 days, looser than FY21's −173.
The full loop: cash goes out to suppliers and production on day 0; stock waits 269 days to sell; customers pay about 20 days after that; and suppliers themselves are paid at 318 days — netting out to the −28-day cycle.
In money terms: at FY26 sales of ₹4,485 Cr, each day of the cycle holds about ₹12.3 Cr — so the −28-day loop keeps roughly ₹−344 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹5,173 Cr over the last 3 fiscal years against ₹758 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹344 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
India Cements Ltd earns a ROCE of 1% in FY26. That is up from a trough of −5% in FY25. Return on invested capital clears the cost of that capital by −10.7 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is −1.5% net margin on 0.33× asset turns.
FY26 ROCE is 1%, recovered from a FY25 trough of −5% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): −1.5% net margin × 0.33× asset turns × 1.32× balance-sheet leverage ≈ −0.7% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 1.3% − 12.0% = a −10.7 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
India Cements Ltd carries total debt of ₹1,305 Cr against shareholder equity of ₹10,124 Cr as of Jun 26, a debt-to-equity of 0.13 — effectively unlevered. On the annual view that ratio went from 0.51 in FY22 to 0.13 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Jun 26: total debt of ₹1,305 Cr against shareholder equity of ₹10,124 Cr — a debt-to-equity of 0.13. On the annual view, debt-to-equity went from 0.51 (FY22) to 0.13 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 46.6 points of India Cements Ltd over 8 quarters, the biggest move on the register. That takes promoters to 75.0% of the company. Foreign institutions moved −14.2 points over the same window, to 3.4%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +46.6 points over 8 quarters to 75.0%; Foreign institutions: −14.2 points over 8 quarters to 3.4%; Domestic institutions: +6.8 points over 8 quarters to 12.6%.
Why the register moved: rotation — foreign institutions −14.2 points against domestic institutions +6.8 points over 8 quarters, with promoters +46.6 points — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
India Cements Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Rain Industries LtdRAIN | 69.8/100Favorable setup75% evidence | LEADER | 28.4/35 Revenue 17% · PAT 100% · OPM change 5 pp 95% evidence | 10.5/25 ROCE 8.3% · OPM 19% 76% evidence | 10.9/20 P/E 13.1× · PEG — 15% evidence | 20.0/20 RS sector 50.4% · RS bench 37.5% · 1Y 30.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.4 + 10.5 + 10.9 + 20 = 69.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Star Cement LtdSTARCEMENT | 69.4/100Favorable setup94% evidence | ASLEEP | 25.6/35 Revenue 14.5% · PAT 55.1% · OPM change -4 pp 100% evidence | 20.2/25 ROCE 16.7% · OPM 21% 100% evidence | 11.4/20 P/E 21.4× · PEG 1.11 100% evidence | 12.2/20 RS sector 13.8% · RS bench -13.7% · 1Y -23%0 of 10 weeks ahead 70% evidence |
| Exact sum: 25.6 + 20.2 + 11.4 + 12.2 = 69.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3UltraTech Cement LtdULTRACEMCO | 64.1/100Mixed-positive evidence76% evidence | ASLEEP | 23.2/35 Revenue 17.2% · PAT 26.7% · OPM change -1 pp 95% evidence | 17.1/25 ROCE 12.7% · OPM 20% 76% evidence | 9.5/20 P/E 39.7× · PEG — 50% evidence | 14.3/20 RS sector 17% · RS bench -4.1% · 1Y -4.4%0 of 10 weeks ahead 70% evidence |
| Exact sum: 23.2 + 17.1 + 9.5 + 14.3 = 64.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 4NCL Industries LtdNCLIND | 60.9/100Mixed-positive evidence87% evidence | ASLEEP | 23.2/35 Revenue 3.7% · PAT 100% · OPM change -3 pp 95% evidence | 18.1/25 ROCE 14.5% · OPM 12% 95% evidence | 9.4/20 P/E 6.3× · PEG — 50% evidence | 10.2/20 RS sector -1.7% · RS bench -11% · 1Y -17.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 23.2 + 18.1 + 9.4 + 10.2 = 60.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Orient Cement LtdORIENTCEM | 58.6/100Mixed-positive evidence93% evidence | ASLEEP | 17.9/35 Revenue -12.1% · PAT -19.3% · OPM change 3 pp 100% evidence | 16.9/25 ROCE 16.5% · OPM 24% 100% evidence | 16.1/20 P/E 12.8× · PEG 0.25 65% evidence | 7.7/20 RS sector -12.1% · RS bench -21.1% · 1Y -43.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.9 + 16.9 + 16.1 + 7.7 = 58.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Mangalam Cement LtdMANGLMCEM | 58.5/100Mixed-positive evidence100% evidence | FADING | 18.1/35 Revenue 0.5% · PAT 90% · OPM change -5 pp 100% evidence | 10.6/25 ROCE 11% · OPM 12% 100% evidence | 16.0/20 P/E 19× · PEG 0.6 100% evidence | 13.8/20 RS sector 17% · RS bench 6.9% · 1Y 23%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 10.6 + 16 + 13.8 = 58.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7HeidelbergCement India LtdHEIDELBERG | 56.6/100Mixed-positive evidence100% evidence | BASING | 15.7/35 Revenue 6.6% · PAT 2.6% · OPM change -4 pp 100% evidence | 14.9/25 ROCE 14.7% · OPM 11% 100% evidence | 13.7/20 P/E 29.5× · PEG 0.82 100% evidence | 12.3/20 RS sector 0.3% · RS bench -9.4% · 1Y -24.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 14.9 + 13.7 + 12.3 = 56.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 8Dalmia Bharat LtdDALBHARAT | 55.5/100Mixed-positive evidence94% evidence | TURNING | 14.3/35 Revenue 7.6% · PAT 0.4% · OPM change -3 pp 100% evidence | 13.2/25 ROCE 7.6% · OPM 21% 100% evidence | 15.4/20 P/E 31.4× · PEG 0.72 100% evidence | 12.6/20 RS sector 12.6% · RS bench -9.5% · 1Y -17.9%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.3 + 13.2 + 15.4 + 12.6 = 55.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 9JSW Cement LtdJSWCEMENT | 52.4/100Thin evidence · provisional52% evidence | FADING | 19.2/35 Revenue 15.6% · PAT 100% · OPM change -5 pp 71% evidence | 11.8/25 ROCE 11.1% · OPM 16% 76% evidence | 10.2/20 P/E 22.5× · PEG — 15% evidence | 11.2/20 RS sector — · RS bench -0.9% · 1Y -11%3 of 10 weeks ahead 25% evidence |
| Exact sum: 19.2 + 11.8 + 10.2 + 11.2 = 52.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10Shree Cement LtdSHREECEM | 50.3/100Mixed-positive evidence97% evidence | ASLEEP | 15.8/35 Revenue 12.6% · PAT 9.9% · OPM change -5 pp 95% evidence | 13.3/25 ROCE 10.3% · OPM 20% 95% evidence | 9.7/20 P/E 54.9× · PEG 0.96 100% evidence | 11.5/20 RS sector 1.5% · RS bench -8.1% · 1Y -18.5%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.8 + 13.3 + 9.7 + 11.5 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11J K Cements LtdJKCEMENT | 49.4/100Mixed-negative evidence94% evidence | ASLEEP | 12.1/35 Revenue 15.9% · PAT -7.1% · OPM change -5 pp 100% evidence | 16.7/25 ROCE 15.1% · OPM 16% 100% evidence | 8.2/20 P/E 42× · PEG 1.46 100% evidence | 12.4/20 RS sector 10.4% · RS bench -8.8% · 1Y -24.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.1 + 16.7 + 8.2 + 12.4 = 49.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Nuvoco Vistas Corporation LtdNUVOCO | 49.3/100Mixed-negative evidence87% evidence | ASLEEP | 22.1/35 Revenue 9.5% · PAT 100% · OPM change 0 pp 100% evidence | 10.2/25 ROCE 7% · OPM 18% 100% evidence | 4.9/20 P/E 28.5× · PEG 8.14 65% evidence | 12.1/20 RS sector 3.6% · RS bench -8% · 1Y -24.7%4 of 10 weeks ahead 70% evidence |
| Exact sum: 22.1 + 10.2 + 4.9 + 12.1 = 49.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Prism Johnson LtdPRSMJOHNSN | 45.8/100Mixed-negative evidence61% evidence | ASLEEP | 18.1/35 Revenue 4.8% · PAT 100% · OPM change 2 pp 71% evidence | 7.0/25 ROCE 5.9% · OPM 12% 76% evidence | 9.2/20 P/E 45.1× · PEG — 15% evidence | 11.5/20 RS sector 14.3% · RS bench -21.4% · 1Y -28.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 18.1 + 7 + 9.2 + 11.5 = 45.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14JK Lakshmi Cement LtdJKLAKSHMI | 45.0/100Mixed-negative evidence69% evidence | ASLEEP | 14.7/35 Revenue 8.7% · PAT 0.5% · OPM change -4 pp 95% evidence | 14.1/25 ROCE 12% · OPM 14% 76% evidence | 10.7/20 P/E 17.7× · PEG — 15% evidence | 5.5/20 RS sector -8.2% · RS bench -24.7% · 1Y -39.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 14.7 + 14.1 + 10.7 + 5.5 = 45 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15India Cements Ltdthis pageINDIACEM | 44.8/100Mixed-negative evidence75% evidence | ASLEEP | 21.0/35 Revenue 7% · PAT 100% · OPM change 7 pp 74% evidence | 3.7/25 ROCE 1.2% · OPM 15% 100% evidence | 5.9/20 P/E 86.2× · PEG — 50% evidence | 14.2/20 RS sector 20% · RS bench -8.2% · 1Y 5.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 3.7 + 5.9 + 14.2 = 44.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Birla Corporation LtdBIRLACORPN | 43.5/100Mixed-negative evidence94% evidence | ASLEEP | 18.6/35 Revenue 3.9% · PAT 44.6% · OPM change -1 pp 100% evidence | 11.0/25 ROCE 9.8% · OPM 13% 100% evidence | 9.1/20 P/E 12.5× · PEG 3.92 100% evidence | 4.8/20 RS sector -14% · RS bench -15.3% · 1Y -27.6%3 of 9 weeks ahead 70% evidence |
| Exact sum: 18.6 + 11 + 9.1 + 4.8 = 43.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17ACC LtdACC | 43.2/100Mixed-negative evidence94% evidence | ASLEEP | 9.7/35 Revenue 11.6% · PAT -21.1% · OPM change -5 pp 100% evidence | 9.9/25 ROCE 11.2% · OPM 8% 100% evidence | 17.0/20 P/E 13.1× · PEG 0.92 100% evidence | 6.6/20 RS sector -6.7% · RS bench -18.5% · 1Y -26.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 9.7 + 9.9 + 17 + 6.6 = 43.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 18K C P LtdKCP | 41.8/100Mixed-negative evidence81% evidence | ASLEEP | 8.0/35 Revenue 6.5% · PAT -17.1% · OPM change -8 pp 95% evidence | 14.3/25 ROCE 12.2% · OPM 8% 95% evidence | 14.2/20 P/E 11.4× · PEG — 50% evidence | 5.3/20 RS sector -14% · RS bench -12% · 1Y -21.3%3 of 11 weeks ahead 70% evidence |
| Exact sum: 8 + 14.3 + 14.2 + 5.3 = 41.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19The Ramco Cements LtdRAMCOCEM | 41.3/100Mixed-negative evidence94% evidence | BASING | 18.6/35 Revenue 8.6% · PAT 100% · OPM change -6 pp 100% evidence | 9.2/25 ROCE 6.1% · OPM 13% 100% evidence | 1.5/20 P/E 112× · PEG 4.14 100% evidence | 12.0/20 RS sector 11.1% · RS bench -11.1% · 1Y -15.4%0 of 10 weeks ahead 70% evidence |
| Exact sum: 18.6 + 9.2 + 1.5 + 12 = 41.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Sagar Cements LtdSAGCEM | 41.2/100Mixed-negative evidence72% evidence | ASLEEP | 20.0/35 Revenue 13.4% · PAT 79.7% · OPM change -8 pp 95% evidence | 5.1/25 ROCE 2% · OPM 10% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.1/20 RS sector -6.8% · RS bench -16.1% · 1Y -23.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 5.1 + 10 + 6.1 = 41.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Ambuja Cements LtdAMBUJACEM | 40.3/100Mixed-negative evidence82% evidence | ASLEEP | 10.6/35 Revenue 7.1% · PAT -5.9% · OPM change -2 pp 95% evidence | 11.0/25 ROCE 5.6% · OPM 17% 76% evidence | 12.8/20 P/E 22× · PEG — 50% evidence | 5.9/20 RS sector -8.6% · RS bench -17.4% · 1Y -28%0 of 12 weeks ahead 100% evidence |
| Exact sum: 10.6 + 11 + 12.8 + 5.9 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22BIGBLOC Construction LtdBIGBLOC | 35.9/100Mixed-negative evidence72% evidence | ASLEEP | 18.8/35 Revenue 33.5% · PAT 11.3% · OPM change 5.6 pp 71% evidence | 6.1/25 ROCE 1.9% · OPM 7.9% 95% evidence | 8.5/20 P/E 379× · PEG — 15% evidence | 2.5/20 RS sector -10.6% · RS bench -18.9% · 1Y -12.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.8 + 6.1 + 8.5 + 2.5 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Saurashtra Cement LtdSAURASHCEM | 35.4/100Mixed-negative evidence80% evidence | ASLEEP | 14.5/35 Revenue 7.9% · PAT -52.1% · OPM change -3.7 pp 95% evidence | 5.3/25 ROCE 2.5% · OPM 4.5% 95% evidence | 9.4/20 P/E 41.9× · PEG — 15% evidence | 6.2/20 RS sector -13.9% · RS bench -23% · 1Y -48.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 5.3 + 9.4 + 6.2 = 35.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Deccan Cements LtdDECCANCE | 33.0/100Adverse evidence80% evidence | ASLEEP | 14.1/35 Revenue 39.4% · PAT -48.2% · OPM change -10.8 pp 95% evidence | 7.5/25 ROCE 3.3% · OPM 7.7% 95% evidence | 10.1/20 P/E 28.1× · PEG — 15% evidence | 1.3/20 RS sector -20.4% · RS bench -28.7% · 1Y -48%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 7.5 + 10.1 + 1.3 = 33 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 25Shree Digvijay Cement Co. LtdSHREDIGCEM | 32.1/100Adverse evidence81% evidence | ASLEEP | 12.1/35 Revenue 19.6% · PAT -35% · OPM change -3.5 pp 95% evidence | 8.5/25 ROCE 6.4% · OPM 8.7% 95% evidence | 5.5/20 P/E 59.1× · PEG — 50% evidence | 6.0/20 RS sector -12.4% · RS bench -11% · 1Y -11.4%3 of 10 weeks ahead 70% evidence |
| Exact sum: 12.1 + 8.5 + 5.5 + 6 = 32.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Shiva Cement LtdSHIVACEM | 36.5/100Thin evidence · provisional42% evidence | 18.1/35 Revenue 19.7% · PAT -47.1% · OPM change 15 pp 40% evidence | 5.4/25 ROCE -3% · OPM 1% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.0/20 RS sector -27.5% · RS bench -36.4% · 1Y -51.7%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 18.1 + 5.4 + 10 + 3 = 36.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is India Cements Ltd's share price today?
India Cements Ltd trades at ₹375, +1.7% over the past year. The company is valued at ₹11,630 Cr. The stock sits at 17% of its 52-week range of ₹354–₹479, −4.1% versus its 200-day average. On the tape, the price is in a downtrend, 1 weeks in. — as of 14 August 2026.
What were India Cements Ltd's latest quarterly results?
India Cements Ltd reported revenue of ₹1,019 Cr and net profit of ₹27.0 Cr for the Jun 26 quarter. Earnings per share were ₹0.87. The operating margin was 15.0%, 7.0 pp higher than a year earlier. — as of 14 August 2026.
What is India Cements Ltd's revenue?
India Cements Ltd reported revenue of ₹1,019 Cr in the Jun 26 quarter, −0.6% year on year. For the full FY26 fiscal year, revenue was ₹4,485 Cr (+8.3%). Over the last 10 years revenue compounded at −0.8% a year. — as of 14 August 2026.
What is India Cements Ltd's profit?
India Cements Ltd earned ₹27.0 Cr of net profit in the Jun 26 quarter. Full-year FY26 profit was ₹−67.0 Cr. The operating margin ran 15.0% in the latest quarter. — as of 14 August 2026.
What is India Cements Ltd's market cap?
India Cements Ltd's market capitalisation is ₹11,630 Cr at a share price of ₹375. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 14 August 2026.
What is India Cements Ltd's P/E ratio?
India Cements Ltd trades at a P/E of 86.2×, at the 83rd percentile of its own 10-year range, against a long-run median of 41.9×. This is a comparison with the stock's own history, not a value call — as of 14 August 2026.
Does India Cements Ltd pay a dividend?
Not in its latest year — India Cements Ltd's dividend payout was 0% of profit in FY26. It did record a payout in 7 of its last 13 reported fiscal years, so there is a history but no current dividend. This page holds the payout ratio, not a per-share amount. — as of 14 August 2026.
Is India Cements Ltd overvalued?
On its own history, India Cements Ltd looks expensive: its P/E of 86.2× sits at the 83rd percentile of its 10-year range (long-run median 41.9×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 14 August 2026.
How is India Cements Ltd performing?
India Cements Ltd is in a downtrend, 1 weeks in. Against the NIFTY 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 14 August 2026.
Is India Cements Ltd in an uptrend?
No — the price is in a downtrend (week 1 of stage 4), trading −4.1% versus its 200-day average and at 17% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 14 August 2026.
Is India Cements Ltd beating the market?
Not lately — on a trailing-13-week view India Cements Ltd is currently behind the NIFTY 500 (2 weeks and counting; last ahead the week of 2026-07-31), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.5 years the stock moved +456% against the NIFTY 500's +284% — ahead of the index over the full window. — as of 14 August 2026.
Will India Cements Ltd's share price go up?
This page publishes no price forecast for India Cements Ltd. What it measures instead: the share price is ₹375, the price is in a downtrend 1 weeks in. Its P/E of 86.2× sits at the 83rd percentile of its own 10-year range. — as of 14 August 2026.
Who owns India Cements Ltd?
Promoters hold 75.0% of India Cements Ltd, foreign institutions 3.4%, domestic institutions 12.6% and the public 9.0% (latest quarter). The biggest move on the register over the last two years: Promoters added 46.6 points over 8 quarters. — as of 14 August 2026.
Does India Cements Ltd have too much debt?
No — India Cements Ltd's debt-to-equity is 0.13, and operating profit covers the interest bill 4×. FY26 borrowings were ₹1,305 Cr against equity of ₹10,124 Cr. The returns on this page are earned, not borrowed — as of 14 August 2026.
What is India Cements Ltd's capex?
India Cements Ltd spent ₹5,173 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹15.0 Cr, with ₹344 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 14 August 2026.
What is India Cements Ltd's cash flow?
India Cements Ltd consumed ₹27.0 Cr of operating cash in FY26 — cash flowed out rather than in (free cash flow: ₹−42.0 Cr). Reported profit that year was ₹−67.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 14 August 2026.
Is India Cements Ltd's profit real cash?
Yes — over the last 3 fiscal years, 539% of India Cements Ltd's reported profit arrived as operating cash. Though the latest year ran at 40% — the trend is the thing to watch. In FY26, operating cash was ₹−27.0 Cr against reported profit of ₹−67.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 14 August 2026.
Where is India Cements Ltd in its business cycle?
India Cements Ltd's FY26 operating margin was 9.0%, against a 13-year band of −8.0%–18.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 15.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 14 August 2026.
What could break the India Cements Ltd story?
Biggest watch item: the P/E sits at the 83rd percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 14 August 2026.
Is India Cements Ltd a stock worth studying right now?
This is not investment advice. The machine read: India Cements Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 14 August 2026.